Last checked at GLOBAL MARKETS ROUNDUP* Nifty futures on the Singapore Exchange are down 0.02percent, while the MSCI-Asia Pacific excluding Japan index was lower 0.23 percent. * Asian share markets were in hesitant mood on Wednesday asinvestors keep a wary eye on interest rates in China, though theeuro left the dollar in its dust after more soft U.S. economicdata. * The S&P 500 and Nasdaq rose on Tuesday, following WallStreet's biggest weekly gain of the year, as merger activityincreased confidence that there is value in the stock marketeven as the benchmark index nears a record high. KEY FACTORS/EVENTS TO WATCH* India's currency, debt and money markets will be closed onWednesday for a public holiday. Stock markets will be open forregular trading hours. * Bank of England, FOMC meet minutes INDIAN STOCKS TO WATCHFor additional press items double click NOTE: Reuters has not verified third-party stories and does notvouch for their accuracy. U.S. regulator on India visit calls for greater drug safetycollaboration - Coal India units see double-digit output growth in 2014/15 - India's fin min says c.bank must abide by govt focus ongrowth - IMG meet on Feb 25 to review coal field awards - Mint (http://link.reuters.com/fuc96v) Tech Mahindra and Financial Technologies come closer on dealtalks - Economic Times (http://link.reuters.com/guc96v) Stemcor may cut India iron pellet output due to poor demand,tax - Gold smuggling in India likely to rise if curbs stay-WGC - Essar Energy to mothball unit at Stanlow refinery - General Mills shopping for food deals in emerging markets EDF in talks to buy stake in GMR's Nepal project - Mint (http://link.reuters.com/duc96v) IDFC sees a revenue loss of 60 percent in Delhi-GurgaonExpressway - Business Standard (http://link.reuters.com/muc96v) Oil and gas auction might be put on hold - Business Standard (http://link.reuters.com/nuc96v) IL&FS Infra debt fund raises up to 15 billion rupees -Economic Times (http://link.reuters.com/puc96v) (Compiled by Dipika Lalwani)
2 May 2024 19:57
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.
Read more
